UMR_S 1256, NGERE - Nutrition, Genetics, and Environmental Risk Exposure, INSERM, University of Lorraine, 54000, Nancy, France.
National Center of Inborn Errors of Metabolism, University Regional Hospital Center of Nancy, 54000, Nancy, France.
Hum Genet. 2022 Jul;141(7):1239-1251. doi: 10.1007/s00439-021-02350-8. Epub 2021 Oct 15.
Inherited disorders of cobalamin (cbl) metabolism (cblA-J) result in accumulation of methylmalonic acid (MMA) and/or homocystinuria (HCU). Clinical presentation includes ophthalmological manifestations related to retina, optic nerve and posterior visual alterations, mainly reported in cblC and sporadically in other cbl inborn errors.We searched MEDLINE EMBASE and Cochrane Library, and analyzed articles reporting ocular manifestations in cbl inborn errors. Out of 166 studies a total of 52 studies reporting 163 cbl and 24 mut cases were included. Ocular manifestations were found in all cbl defects except for cblB and cblD-MMA; cblC was the most frequent disorder affecting 137 (84.0%) patients. The c.271dupA was the most common pathogenic variant, accounting for 70/105 (66.7%) cases. One hundred and thirty-seven out of 154 (88.9%) patients presented with early-onset disease (0-12 months). Nystagmus and strabismus were observed in all groups with the exception of MMA patients while maculopathy and peripheral retinal degeneration were almost exclusively found in MMA-HCU patients. Optic nerve damage ranging from mild temporal disc pallor to complete atrophy was prevalent in MMA-HCU.and MMA groups. Nystagmus was frequent in early-onset patients. Retinal and macular degeneration worsened despite early treatment and stabilized systemic function in these patients. The functional prognosis remains poor with final visual acuity < 20/200 in 55.6% (25/45) of cases. In conclusion, the spectrum of eye disease in Cbl patients depends on metabolic severity and age of onset. The development of visual manifestations over time despite early metabolic treatment point out the need for specific innovative therapies.
钴胺素(cbl)代谢遗传障碍(cblA-J)导致甲基丙二酸(MMA)和/或高半胱氨酸尿症(HCU)积累。临床表现包括与视网膜、视神经和后部视觉改变相关的眼部表现,主要见于 cblC,偶尔见于其他 cbl 先天性错误。我们搜索了 MEDLINE、EMBASE 和 Cochrane 图书馆,并分析了报道 cbl 先天性错误中眼部表现的文章。在 166 项研究中,共纳入了 52 项研究,报道了 163 例 cbl 和 24 例突变病例。除了 cblB 和 cblD-MMA,所有 cbl 缺陷都发现了眼部表现;cblC 是最常见的疾病,影响了 137(84.0%)名患者。c.271dupA 是最常见的致病性变异,占 70/105(66.7%)例。154 例中有 137 例(88.9%)患者出现早发性疾病(0-12 个月)。除了 MMA 患者外,所有组都观察到眼球震颤和斜视,而黄斑病变和周边视网膜变性几乎只存在于 MMA-HCU 患者中。MMA-HCU 和 MMA 组均存在从轻度颞盘苍白到完全萎缩的视神经损伤。早发性患者中眼球震颤频繁。尽管早期治疗改善了视网膜和黄斑变性,但仍使这些患者的系统功能稳定。尽管最终视力<20/200,但功能预后仍较差,55.6%(25/45)的病例视力<20/200。总之,Cbl 患者眼病的范围取决于代谢严重程度和发病年龄。尽管早期代谢治疗,但随着时间的推移视觉表现仍在发展,这表明需要特定的创新疗法。